{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rare+Genetic+Disorders&page=6",
    "query": {
      "condition": "Rare Genetic Disorders",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 191,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rare+Genetic+Disorders&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rare+Genetic+Disorders&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T14:07:17.031Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05358717",
      "title": "A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington Disease"
      ],
      "interventions": [
        {
          "name": "PTC518",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2022-06-03",
      "completion_date": "2025-07-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 4,
      "location_summary": "La Jolla, California • Nashville, Tennessee • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05358717"
    },
    {
      "nct_id": "NCT02543996",
      "title": "Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Undiagnosed Diseases",
        "Cardiovascular Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "1 Month to 100 Years"
      },
      "enrollment_count": 10000,
      "start_date": "2015-09-17",
      "completion_date": "2050-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543996"
    },
    {
      "nct_id": "NCT01733316",
      "title": "Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystinosis"
      ],
      "interventions": [
        {
          "name": "RP103",
          "type": "DRUG"
        },
        {
          "name": "Cystagon®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2013-01-31",
      "completion_date": "2017-07-10",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Stanford, California • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01733316"
    },
    {
      "nct_id": "NCT00004404",
      "title": "Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "clotrimazole",
          "type": "DRUG"
        },
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "1997-04",
      "completion_date": "2002-09",
      "has_results": false,
      "last_update_posted_date": "2015-03-25",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004404"
    },
    {
      "nct_id": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adrenal Cortical Carcinoma",
        "Alveolar Soft Part Sarcoma",
        "Central Nervous System Neoplasm",
        "Childhood Clear Cell Sarcoma of Soft Tissue",
        "Clear Cell Sarcoma of Soft Tissue",
        "Ewing Sarcoma",
        "Hepatoblastoma",
        "Hepatocellular Carcinoma",
        "Osteosarcoma",
        "Recurrent Adrenal Cortical Carcinoma",
        "Recurrent Alveolar Soft Part Sarcoma",
        "Recurrent Clear Cell Sarcoma of Soft Tissue",
        "Recurrent Ewing Sarcoma",
        "Recurrent Hepatoblastoma",
        "Recurrent Hepatocellular Carcinoma",
        "Recurrent Kidney Wilms Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Osteosarcoma",
        "Recurrent Primary Malignant Central Nervous System Neoplasm",
        "Recurrent Renal Cell Carcinoma",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Recurrent Thyroid Gland Medullary Carcinoma",
        "Refractory Adrenal Cortical Carcinoma",
        "Refractory Alveolar Soft Part Sarcoma",
        "Refractory Clear Cell Sarcoma of Soft Tissue",
        "Refractory Ewing Sarcoma",
        "Refractory Hepatoblastoma",
        "Refractory Hepatocellular Carcinoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Osteosarcoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Refractory Primary Malignant Central Nervous System Neoplasm",
        "Refractory Renal Cell Carcinoma",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Refractory Thyroid Gland Medullary Carcinoma",
        "Refractory Wilms Tumor",
        "Renal Cell Carcinoma",
        "Rhabdomyosarcoma",
        "Soft Tissue Sarcoma",
        "Solid Neoplasm",
        "Thyroid Gland Medullary Carcinoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "2 Years to 30 Years"
      },
      "enrollment_count": 109,
      "start_date": "2017-05-18",
      "completion_date": "2027-06-28",
      "has_results": true,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 142,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02867592"
    },
    {
      "nct_id": "NCT06795152",
      "title": "Rare Glycogen Storage Diseases Natural History Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glycogen Storage Disease",
        "GSD Type 0A",
        "GSD Type 0B",
        "GSD VII",
        "Tarui Disease",
        "GSD X",
        "GSD XII",
        "GSD XIII",
        "GSD XV",
        "PGBM2",
        "PRKAG2",
        "Danon Disease",
        "Polyglucosan Body Myopathy Type 1",
        "Polyglucosan Body Myopathy Type 2",
        "RBCK1 Deficiency"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "0 Years to 90 Years"
      },
      "enrollment_count": 200,
      "start_date": "2024-12-23",
      "completion_date": "2034-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06795152"
    },
    {
      "nct_id": "NCT00872729",
      "title": "Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cystinosis"
      ],
      "interventions": [
        {
          "name": "Cystagon®",
          "type": "DRUG"
        },
        {
          "name": "RP103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 9,
      "start_date": "2009-05",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00872729"
    },
    {
      "nct_id": "NCT04771416",
      "title": "Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukodystrophy, Globoid Cell"
      ],
      "interventions": [
        {
          "name": "PBKR03",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gemma Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "9 Months",
        "sex": "ALL",
        "summary": "1 Month to 9 Months"
      },
      "enrollment_count": 24,
      "start_date": "2022-02-24",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04771416"
    },
    {
      "nct_id": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma, ALK-Negative",
        "Anaplastic Large Cell Lymphoma, ALK-Positive",
        "Apocrine Carcinoma",
        "Carcinoma Arising From Cylindroma",
        "Carcinoma Arising From Spiradenoma",
        "Digital Papillary Adenocarcinoma",
        "Endocrine Mucin-Producing Sweat Gland Carcinoma",
        "Extramammary Paget Disease",
        "Extraocular Sebaceous Carcinoma",
        "Hidradenocarcinoma",
        "Malignant Sweat Gland Neoplasm",
        "Merkel Cell Carcinoma",
        "Microcystic Adnexal Carcinoma",
        "NK-Cell Lymphoma, Unclassifiable",
        "Papillary Adenocarcinoma",
        "Porocarcinoma",
        "Primary Cutaneous Mucinous Carcinoma",
        "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Recurrent T-Cell Non-Hodgkin Lymphoma",
        "Refractory Anaplastic Large Cell Lymphoma",
        "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Refractory Merkel Cell Carcinoma",
        "Refractory Mycosis Fungoides",
        "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Refractory Skin Squamous Cell Carcinoma",
        "Refractory T-Cell Non-Hodgkin Lymphoma",
        "Sezary Syndrome",
        "Signet Ring Cell Adenocarcinoma",
        "Skin Adenoid Cystic Carcinoma",
        "Skin Adnexal Carcinoma",
        "Skin Basal Cell Carcinoma",
        "Skin Basosquamous Cell Carcinoma",
        "Skin Keratoacanthoma",
        "Skin Squamous Cell Carcinoma",
        "Squamoid Eccrine Ductal Carcinoma",
        "Squamous Cell Carcinoma of Unknown Primary",
        "Sweat Gland Carcinoma",
        "Trichilemmal Carcinoma",
        "Vulvar Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Talimogene Laherparepvec",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2017-09-27",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 36,
      "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 28 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978625"
    },
    {
      "nct_id": "NCT06560346",
      "title": "Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Friedreich Ataxia",
        "Rare Diseases"
      ],
      "interventions": [
        {
          "name": "Geneticlly confirmed disease causing FXN mutatuion",
          "type": "OTHER"
        },
        {
          "name": "Healthy Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Friedreich's Ataxia Research Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "4 Years to 21 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-05-01",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-08",
      "last_synced_at": "2026-11-19T14:07:17.031Z",
      "location_count": 3,
      "location_summary": "Iowa City, Iowa • Philadelphia, Pennsylvania • Memphis, Tennessee",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06560346"
    }
  ]
}